P16 Loss and E2F/cell cycle deregulation in infant posterior fossa ependymoma.

ABSTRACT:

Background

Posterior fossa (PF) ependymomas (EPNs) in infants less than 1 year of age (iEPN-PF) have a poorer clinical outcome than EPNs in older children. While radiation therapy is the standard of care for the latter, it is withheld in infants to avoid neurotoxicity to immature brain. It is unknown whether the adverse outcome in iEPN-PFs is due to treatment differences or aggressive biology. We examined this question using molecular profiling.

Methods

Six anaplastic iEPN-PFs were subjected to transcriptomic analysis and FISH for p16 loss and gains of 1q, and compared with anaplastic PF EPNs from older children. Results were validated by immunohistochemistry (IHC).

Results

All six iEPN-PFs were grouped within EPN PF subgroup A (PFA). E2F targets and G2M checkpoint we

SUBMITTER: Lummus SC 

PROVIDER: S-EPMC5647247 | biostudies-literature | 2017 Dec

REPOSITORIES: biostudies-literature